Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
J Infect Dis. 2019 Apr 8;219(Suppl_1):S5-S13. doi: 10.1093/infdis/jiy728.
The year 2018 marked the 100th anniversary of the deadliest event in human history. In 1918-1919, pandemic influenza spread globally and caused an estimated 50-100 million deaths associated with unexpected clinical and epidemiological features. The descendants of the 1918 virus continue to circulate as annual epidemic viruses causing significant mortality each year. The 1918 influenza pandemic serves as a benchmark for the development of universal influenza vaccines. Challenges to producing a truly universal influenza vaccine include eliciting broad protection against antigenically different influenza viruses that can prevent or significantly downregulate viral replication and reduce morbidity by preventing development of viral and secondary bacterial pneumonia. Perhaps the most important goal of such vaccines is not to prevent influenza, but to prevent influenza deaths.
2018 年标志着人类历史上最致命事件的 100 周年。1918-1919 年,大流行性流感在全球范围内传播,导致与意想不到的临床和流行病学特征相关的估计有 5000 万至 1 亿人死亡。1918 年病毒的后代继续作为每年引起重大死亡率的流行性病毒循环。1918 年流感大流行是开发通用流感疫苗的基准。生产真正通用流感疫苗的挑战包括针对具有不同抗原性的流感病毒引发广泛保护,从而可以预防或显著下调病毒复制并通过预防病毒和继发性细菌性肺炎的发展来降低发病率。此类疫苗最重要的目标也许不是预防流感,而是预防流感死亡。